Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered syste...
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
About this item
Full title
Author / Creator
Davar, Diwakar , Carneiro, Benedito A , Dy, Grace K , Sheth, Siddharth , Borad, Mitesh J , Harrington, Kevin J , Patel, Sandip P , Galanis, Evanthia , Samson, Adel , Agrawal, Sonia , Chen, Zhongying , Fan, Chunling , Gong, Maozhen , Burton, Jenny , Tu, Eric , Durham, Nicholas , Laubscher, Kevin , Arnaldez, Fernanda and Zamarin, Dmitriy
Publisher
England: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
BackgroundMEDI5395 is a recombinant attenuated Newcastle disease virus engineered to express a human granulocyte-macrophage colony-stimulating factor transgene. Preclinically, MEDI5395 demonstrated broad oncolytic activity, augmented by concomitant programmed cell death-1/programmed cell death ligand-1 (PD-L1) axis blockade. Durvalumab is an anti-P...
Alternative Titles
Full title
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9b8ca43a8d514a34aab835d920738e15
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9b8ca43a8d514a34aab835d920738e15
Other Identifiers
ISSN
2051-1426
E-ISSN
2051-1426
DOI
10.1136/jitc-2024-009336
